BOK Financial’s Coherus Oncology CHRS Stock Holding History

BOK Financial’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-22,285	Closed	-$312K	–	926
2018 Q2	$312K	Buy	+22,285	New	+$319K	0.01%	788

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

BOK Financial's CHRS Position: Q3 2018 in Review

BOK Financial sold out of Coherus Oncology (CHRS) in Q3 2018, closing a stake of 22,285 shares — an estimated $312K sold.

BOK Financial first reported a position in CHRS in Q2 2018 and held it in 1 quarter. The position peaked at $312K in Q2 2018. 109 funds tracked by Wall St. Rank hold CHRS as of Q3 2018.

BOK Financial reported no remaining Coherus Oncology position as of Q3 2018 after selling out during the quarter.
BOK Financial sold 22,285 Coherus Oncology shares in Q3 2018, an estimated $312K.
BOK Financial first reported a position in Coherus Oncology in Q2 2018 and held it in 1 quarter.
BOK Financial's Coherus Oncology position peaked at $312K in Q2 2018.
109 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2018.

Based on BOK Financial's 13F filing for Q3 2018, filed 13 Nov 2018.